• 免費註冊
  • 加入官方line@
  • 加入FB粉絲團

台股 » 個股 » 太景*-KY » 籌碼相關 » 券商分點績效 » 券商分點個股進出

太景*-KY

(4157)
可現股當沖
  • 股價
    11.20
  • 漲跌
    ▲0.40
  • 漲幅
    +3.70%
  • 成交量
    1,923張
  • 產業
    上櫃 生技醫療類股

  • 266人加入追蹤

    立即追蹤

  • 本地時間:14:30

     
太景*-KY (4157)籌碼相關－富邦-台北 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效，來找出真正獲利的贏家所在券商分點，進而追蹤此贏家所操作的股票與軌跡。

股票投資新手教室：一秒知道是否上對大戶列車

富邦-台北 券商分點個股進出

富邦-台北 券商分點全部個股操作績效/獲利分析

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2025/01/200.110.75410.8010.80-3.91,224-0.32%
2025/01/1700.00210.7510.70-21,219-0.16%
2025/01/144.410.7100.0010.704.41,2190.36%
2025/01/1315.410.9600.0010.7015.41,2151.26%
2025/01/1011.111.36711.2211.354.11,1850.35%
2025/01/091.111.0600.0011.251.11,1560.10%
2025/01/0813.111.00111.0511.0512.11,1351.07%
2025/01/073.111.2400.0011.053.11,1220.28%
2025/01/025.111.3500.0011.305.11,1110.46%
2024/12/300.111.4500.0011.300.11,1150.01%
2024/12/2711.111.551011.8511.501.11,1330.10%
2024/12/261411.961211.9712.0021,1560.17%
2024/12/2400.005710.9410.95-571,103-5.16%
2024/12/23110.8500.0010.8511,1160.09%
2024/12/191.511.0500.0010.901.51,1110.13%
2024/12/1700.001011.3011.25-101,110-0.90%
2024/12/160.511.321011.2011.20-9.51,125-0.84%
2024/12/13111.4500.0011.4511,1240.09%
2024/12/10111.90611.8511.85-51,110-0.45%
2024/12/093.211.911011.9011.85-6.81,129-0.60%
2024/12/060.112.0500.0012.000.11,1220.01%
2024/12/05112.1000.0012.0511,1170.09%
2024/12/0200.00212.3512.15-21,133-0.18%
2024/11/290.112.4000.0012.500.11,1280.00%
2024/11/270.312.2300.0012.100.31,1240.03%
2024/11/260.212.3000.0012.300.21,1330.01%
2024/11/254.212.4000.0012.254.21,1210.37%
2024/11/2200.00212.6012.55-2924-0.22%
2024/11/200.212.5000.0012.450.29280.02%
2024/11/18012.2500.0012.2009650.00%
2024/11/15112.0000.0012.0019740.10%
2024/11/144.512.481012.6012.20-5.6932-0.60%
2024/11/134.113.1600.0013.104.18790.47%
2024/11/120.213.4400.0013.250.28820.02%
2024/11/11613.5500.0013.5068650.69%
2024/11/081.213.80213.7013.70-0.8857-0.09%
2024/11/07313.8500.0013.8538670.35%
2024/11/06313.8800.0013.8538930.34%
2024/11/05213.9500.0014.0029180.22%
2024/11/01114.0500.0014.1011,0200.10%
2024/10/30213.9000.0013.8521,0230.20%
2024/10/2900.00414.0513.95-41,025-0.39%
2024/10/241.114.2100.0014.151.11,0280.10%
2024/10/21214.1500.0014.1521,0650.19%
2024/10/1700.00614.2514.35-61,091-0.55%
2024/10/15414.311014.3014.25-61,124-0.53%
2024/10/14414.2800.0014.2541,1340.35%
2024/10/11514.3200.0014.3051,1590.43%
2024/10/092014.5400.0014.40201,1731.70%
2024/10/08414.7800.0014.6541,1870.34%
2024/10/076714.7900.0014.85671,2645.30%
2024/10/04214.8800.0014.8021,3120.15%
2024/10/01114.850.415.1015.100.61,3230.05%
2024/09/30114.95314.8514.95-21,311-0.15%
2024/09/26214.5800.0014.5021,2920.15%
2024/09/250.314.8300.0014.750.31,3060.03%
2024/09/242.414.4600.0014.452.41,3110.18%
2024/09/233.214.5300.0014.403.21,3420.24%
2024/09/20714.6600.0014.6571,3780.51%
2024/09/1800.00214.6514.55-21,398-0.14%
2024/09/1600.001514.3514.40-151,393-1.08%
2024/09/13314.1500.0014.2031,3970.21%
2024/09/1000.008214.2514.50-821,458-5.62%
2024/09/0600.003013.9213.90-301,502-2.00%
2024/09/051.114.0000.0013.901.11,5380.07%
2024/09/04014.007513.9813.95-751,629-4.60%
2024/09/031.114.35614.5514.35-4.91,698-0.29%
2024/09/021514.5800.0014.50151,7410.86%
2024/08/3000.002014.5514.50-201,759-1.14%
2024/08/2900.001614.5514.40-161,760-0.91%
2024/08/28614.6500.0014.6561,7710.34%
2024/08/23014.401414.3214.30-141,814-0.77%
2024/08/20214.70214.9514.8001,8410.00%
2024/08/160.614.651514.6014.55-14.41,812-0.79%
2024/08/1500.00414.6014.45-41,827-0.22%
2024/08/1400.00414.4014.55-41,856-0.22%
2024/08/1300.00314.2514.25-31,899-0.16%
2024/08/12414.2500.0014.2541,9090.21%
2024/08/0915.314.351014.2514.305.31,9140.28%
2024/08/081814.421214.4714.6061,9050.31%
2024/08/06113.35213.6513.35-11,887-0.05%
2024/08/05113.506913.6613.45-681,901-3.57%
2024/08/020.314.13214.0014.00-1.81,840-0.10%
2024/08/010.214.30514.3014.30-4.91,849-0.26%
2024/07/3100.001514.1814.20-151,864-0.80%
2024/07/290.114.1500.0014.050.11,9110.00%
2024/07/260.214.151014.1114.10-9.81,918-0.51%
2024/07/23114.2000.0014.2011,9560.05%
2024/07/220.114.251414.1514.15-13.91,976-0.70%
2024/07/1913.514.3300.0014.3013.51,9790.68%
2024/07/180.314.66414.6014.60-3.72,008-0.18%
2024/07/168.214.503014.5514.50-21.82,249-0.97%
2024/07/157.114.521314.5514.55-5.92,664-0.22%
2024/07/121.114.71214.6514.65-0.92,823-0.03%
2024/07/111314.42314.5214.50102,7980.36%
2024/07/102.214.4900.0014.452.22,8290.08%
2024/07/0986.314.5900.0014.6086.32,8243.05%
2024/07/085.114.912015.0514.90-14.92,748-0.54%
2024/07/05015.1000.0015.1002,7130.00%
2024/07/040.115.151815.0515.05-17.92,703-0.66%
2024/07/0300.00615.1015.05-62,701-0.22%
2024/07/0217.515.021315.1015.054.52,7010.17%
2024/07/01815.13415.2015.1042,7120.15%
2024/06/272515.33315.4015.25222,7260.81%
2024/06/261015.28315.2515.2572,7220.26%
2024/06/253.115.0500.0015.053.12,7140.11%
2024/06/2400.00315.1015.10-32,745-0.11%
2024/06/200.115.1500.0015.100.12,8250.00%
2024/06/1900.00215.0515.05-22,823-0.07%
2024/06/18315.1000.0015.1032,8200.11%
2024/06/17015.2500.0015.3502,8140.00%
2024/06/1400.00715.1015.05-72,792-0.25%
2024/06/13115.0500.0015.0012,7730.04%
2024/06/12115.45515.4515.30-42,734-0.15%
2024/06/112515.582315.8415.5522,7060.07%
2024/06/075015.623215.9015.40182,6490.68%
2024/06/066115.531015.6015.40512,6091.95%
2024/06/05615.3500.0015.4062,5760.23%
2024/06/03015.250.115.2515.20-0.12,6200.00%
2024/05/3100.002515.2715.20-252,616-0.96%
2024/05/301515.35215.3015.35132,6210.50%
2024/05/28215.003115.0515.05-292,616-1.11%
2024/05/27415.08115.1015.0032,6120.11%
2024/05/24215.031015.0815.05-82,617-0.31%
2024/05/236.615.2210.115.2315.20-3.52,616-0.14%
2024/05/22015.5500.0015.5002,6170.00%
2024/05/2100.00215.5815.60-22,619-0.08%
2024/05/20415.66215.6315.6522,6060.08%
2024/05/1700.004315.5715.55-432,580-1.67%
2024/05/1600.001015.1015.10-102,557-0.39%
2024/05/14115.003415.0915.00-332,575-1.28%
2024/05/131.115.1100.0015.051.12,5660.04%
2024/05/101.115.302015.2815.30-18.92,551-0.74%
2024/05/0921.115.394215.3615.35-20.92,540-0.82%
2024/05/08215.0000.0014.9522,4950.08%
2024/05/07314.88514.9014.85-22,493-0.08%
2024/05/06414.9600.0014.9542,4760.16%
2024/05/035415.14715.1115.00472,4781.90%
2024/05/02115.35115.3015.1502,4470.00%
2024/04/30415.4000.0015.3542,4290.16%
2024/04/29115.30115.6515.6502,4070.00%
2024/04/261615.411615.5015.4002,3700.00%
2024/04/25215.60215.5515.5002,3450.00%
2024/04/242015.507415.6215.45-542,326-2.32%
2024/04/232715.634815.5715.50-212,295-0.91%
2024/04/223516.4919416.5915.60-1592,247-7.07% 大賣/鉅額交易
2024/04/194516.998816.8316.45-432,041-2.11%
2024/04/1811315.688015.7515.75331,6212.04% 大買/
2024/04/17114.40314.3514.35-21,451-0.14%
2024/04/165.314.2700.0014.255.31,4490.37%
2024/04/151314.651014.6514.6531,4180.21%
2024/04/11115.053315.0314.90-321,438-2.23%
2024/04/1000.006015.2315.10-601,428-4.20%
2024/04/0800.00315.2015.30-31,431-0.21%
2024/04/033315.16215.1315.05311,4362.16%
2024/04/021415.60215.6515.65121,4150.85%
2024/04/013115.751315.7515.70181,4031.28%
2024/03/29215.45415.7615.45-21,365-0.15%
2024/03/28215.603615.5015.45-341,349-2.52%
2024/03/272715.763015.6315.45-31,324-0.23%
2024/03/262.515.4000.0015.352.51,2980.19%
2024/03/251515.525115.4215.40-361,273-2.83%
2024/03/22214.9000.0014.9021,2360.16%
2024/03/21214.50314.7014.70-11,244-0.08%
2024/03/20714.4100.0014.3571,2380.57%
2024/03/152014.6800.0014.65201,2461.60%
2024/03/1400.00514.7114.60-51,253-0.40%
2024/03/136414.56314.5014.50611,2594.85%
2024/03/123614.932714.9914.9091,2670.71%
2024/03/11414.53214.5014.5521,2460.16%
2024/03/071.114.6000.0014.751.11,4920.07%
2024/03/063.114.7700.0014.703.11,5690.20%
2024/03/05414.8100.0014.8041,5770.25%
2024/03/04015.2000.0014.8501,6300.00%
2024/02/291.115.1500.0015.101.11,8960.06%
2024/02/27015.1000.0015.0001,8920.00%
2024/02/262015.253215.2515.20-121,890-0.63%
2024/02/23015.3900.0015.1001,8790.00%
2024/02/22615.34815.2915.25-21,864-0.11%
2024/02/21515.70415.6315.6511,8490.05%
2024/02/20015.55215.5515.55-21,837-0.11%
2024/02/19415.801115.7115.50-71,835-0.38%
2024/02/1600.001015.4015.40-101,803-0.55%
2024/02/1500.00115.1015.10-11,783-0.06%
2024/02/0500.00214.9014.95-21,792-0.11%
太景抗流感病毒新藥 正式向中國藥監局申請上市許可UDN聯合新聞網－2024/08/04
太景*-KY（4157）4日晚間公告，接獲合作夥伴健康元藥業集團通知，太景開發的抗流感病毒新藥Pixavir (TG-1......詳全文
太景*-KY流感抗病毒新藥三期臨床 提前完成收案750人Anue鉅亨－2024/01/08
...詳全文
太景新藥 取得俄國藥證UDN聯合新聞網－2022/08/29
太景*-KY （4157）昨（28）日代子公司太景生技公告，抗生素新藥奈諾沙星靜脈輸液（500 mg/250 ml）已獲......詳全文
太景*-KY 相關文章